D-Homoserine lactone
(Synonyms: D-HSL) 目录号 : GC48967
An enantiomer of L-homoserine lactone
Cas No.:51744-82-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
D-homoserine lactone is an enantiomer of L-homoserine lactone and an inhibitor of serine hydroxymethyltransferase (SHMT; Ki = 11 mM for the rabbit enzyme).1
1.Wang, E.A., Kallen, R., and Walsh, C.Mechanism-based inactivation of serine transhydroxymethylases by D-fluoroalanine and related amino acidsJ. Biol. Chem.256(13)6917-6926(1981)
| Cas No. | 51744-82-2 | SDF | |
| 别名 | D-HSL | ||
| Canonical SMILES | N[C@H]1C(OCC1)=O | ||
| 分子式 | C4H7NO2 | 分子量 | 101.1 |
| 溶解度 | 储存条件 | -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 9.8912 mL | 49.456 mL | 98.912 mL |
| 5 mM | 1.9782 mL | 9.8912 mL | 19.7824 mL |
| 10 mM | 0.9891 mL | 4.9456 mL | 9.8912 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Resolving Mixed Intermediate Phases in Methylammonium-Free Sn-Pb Alloyed Perovskites for High-Performance Solar Cells
Nanomicro Lett 2022 Aug 16;14(1):165.PMID:35974239DOI:10.1007/s40820-022-00918-1.
The complete elimination of methylammonium (MA) cations in Sn-Pb composites can extend their light and thermal stabilities. Unfortunately, MA-free Sn-Pb alloyed perovskite thin films suffer from wrinkled surfaces and poor crystallization, due to the coexistence of mixed intermediate phases. Here, we report an additive strategy for finely regulating the impurities in the intermediate phase of Cs0.25FA0.75Pb0.6Sn0.4I3 and, thereby, obtaining high-performance solar cells. We introduced D-Homoserine lactone hydrochloride (D-HLH) to form hydrogen bonds and strong Pb-O/Sn-O bonds with perovskite precursors, thereby weakening the incomplete complexation effect between polar aprotic solvents (e.g., DMSO) and organic (FAI) or inorganic (CsI, PbI2, and SnI2) components, and balancing their nucleation processes. This treatment completely transformed mixed intermediate phases into pure preformed perovskite nuclei prior to thermal annealing. Besides, this D-HLH substantially inhibited the oxidation of Sn2+ species. This strategy generated a record efficiency of 21.61%, with a Voc of 0.88 V for an MA-free Sn-Pb device, and an efficiency of 23.82% for its tandem device. The unencapsulated devices displayed impressive thermal stability at 85 °C for 300 h and much improved continuous operation stability at MPP for 120 h.